Monitor for concrete partnership agreements or government funding commitments for opaganib in Ebola. Without a funded development pathway or regulatory milestone, this remains a speculative pipeline update. The company's cash position ($4.1M) and going concern risk dominate the outlook.
Price Chart
Executive Summary
RedHill Biopharma provided an update on its opaganib development for Ebola virus disease (EVD) as the Bundibugyo ebolavirus outbreak has grown to 3,221 cases and 1,407 deaths. The company is in partnership discussions with the African Medicines Agency, Ugandan Ministry of Health, and DRC Scientific Advisory Committee. While this represents a potential catalyst for opaganib, the drug remains unapproved and the company faces severe financial distress with only $4.1M cash, a going concern warning, and ongoing Nasdaq delisting risk, making this a speculative update with no near-term revenue impact.
Key Facts
- Ebola outbreak has grown to 3,221 confirmed cases and 1,407 deaths
- RedHill is in partnership discussions with African Medicines Agency, Ugandan Ministry of Health, and Mbarara University
- Opaganib is an investigational drug not approved by any regulatory authority
- Company has only $4.1M cash remaining with substantial doubt about going concern
- Recent ATM offering allows sale of up to $2.128M in ADSs, adding dilution risk
Financial Impact
No financial figures reported in this filing; company has $4.1M cash per prior 20-F filing
Risk Factors
- Opaganib is not approved and may never be approved for Ebola
- Company faces Nasdaq delisting risk and going concern uncertainty
- Recent ATM offering creates dilution risk for existing shareholders
- Partnership discussions may not result in binding agreements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003601 |
| Document: 0001178913-26-003601-index-headers.html | 0001178913-26-003601 |
| Document: 0001178913-26-003601-index.html | 0001178913-26-003601 |
| Document: 0001178913-26-003601.txt | 0001178913-26-003601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers